Cardiovascular PET imaging of fibroblast activation A review of the current literature.

Autor:	Loganath K; BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom. Electronic address: kloganat@ed.ac.uk., Craig N; BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom., Barton A; BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom., Joshi S; BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom., Anagnostopoulos C; Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation, Academy of Athens, Athens, Greece., Erba PA; Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy; Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Glaudemans AWJM; Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Center, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Saraste A; Turku PET Centre, Turku University Hospital and University of Turku, Kiinamllynkatu, Turku, Finland; Heart Center, Turku University Hospital, Turku, Finland., Bucerius J; Department of Nuclear Medicine, Georg-August University Göttingen, University Medicine Göttingen, Göttingen, Germany., Lubberink M; Department of Surgical Sciences/Radiology, Uppsala University, Uppsala, Sweden., Gheysens O; Department of Nuclear Medicine, Cliniques Universitaires Saint-Luc, Brussels, Belgium., Buechel RR; Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland., Habib G; Cardiology Department, APHM, La Timone Hospital, Marseille, France; Aix Marseille Université, IRD, APHM, MEPHI, IHU-Méditerranée Infection, Marseille, France., Gaemperli O; HeartClinic, Hirslanden Hospital Zurich, Hirslanden, Switzerland., Gimelli A; Fondazione Toscana G. Monasterio, Pisa, Italy., Hyafil F; Department of Nuclear Medicine, DMU IMAGINA, Georges-Pompidou European Hospital, Assistance Publique - Hôpitaux de Paris, University of Paris, Paris, France; PARCC, INSERM, University of Paris, Paris, France., Newby DE; BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom., Slart RHJA; Medical Imaging Centre, Department of Nuclear Medicine & Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands; Faculty of Science and Technology Biomedical, Photonic Imaging, University of Twente, Enschede, The Netherlands., Dweck MR; BHF Centre of Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
Jazyk:	angličtina
Zdroj:	Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology [J Nucl Cardiol] 2024 Dec 11, pp. 102106. Date of Electronic Publication: 2024 Dec 11.
DOI:	10.1016/j.nuclcard.2024.102106
Abstrakt:	Fibrosis is one of the key healing responses to injury, especially within the heart where it helps to maintain structural integrity following acute insults such as myocardial infarction. However, if it becomes dysregulated then fibrosis can become maladaptive leading to adverse remodelling, impaired cardiac function and heart failure. Fibroblast activation protein is exclusively expressed by activated fibroblasts, the key effector cells of fibrogenesis, and has a unique extracellular domain that is an ideal ligand for novel molecular imaging probes. Fibroblast activation protein inhibitor (FAPI) radiotracers have been developed for PET imaging, demonstrating high selectivity for activated fibroblasts across a range of different pathologies and disparate organ systems. In this review, we will summarize the role of fibroblast activation protein in cardiovascular disease and how FAPI radiotracers might improve the assessment and treatment of patients with cardiovascular diseases. Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Paolo Anna Erba reports a relationship with SIEMENS that includes: consulting or advisory and speaking and lecture fees. Paolo Anna Erba reports a relationship with Novartis Pharmaceuticals Corporation that includes: consulting or advisory, funding grants, and speaking and lecture fees. Paolo Anna Erba reports a relationship with Springer Healthcare Limited that includes: equity or stocks. Paolo Anna Erba reports a relationship with Pfizer that includes: funding grants. Antti Saraste reports a relationship with AstraZeneca Pharmaceuticals LP that includes: consulting or advisory and speaking and lecture fees. Antti Saraste reports a relationship with Pfizer that includes: consulting or advisory and funding grants. Antti Saraste reports a relationship with Abbott that includes: speaking and lecture fees. Antti Sarate reports a relationship with Bristol Myers Squibb Co that includes: speaking and lecture fees. Antti Saraste reports a relationship with Janssen Pharmaceuticals Inc that includes: speaking and lecture fees. Jan Bucerius reports a relationship with International Atomic Energy Agency that includes: funding grants, non-financial support, and travel reimbursement. Jan Bucerius reports a relationship with European Association of Nuclear Medicine that includes: board membership. Olivier Gheysens reports a relationship with General Electric Company that includes: speaking and lecture fees. Ronny Buechel reports a relationship with General Electric Company that includes: speaking and lecture fees. Ronny Buechel reports a relationship with Pfizer Inc that includes: speaking and lecture fees. Ronny Buechel reports a relationship with Gilead Sciences Inc that includes: speaking and lecture fees. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu